News | September 10, 2025
Sirio secures TGA GMP certification to support strategic growth in Australia
The Ma’anshan site approval covers pastilles, oral liquids, and powders
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
Subscribe To Our Newsletter & Stay Updated
